NewAmsterdam Pharma Company N.V.
NASDAQ:NAMSBiotechnology
+$0.12 today
- Market cap
- $2.37B
- Beta
- 0.08
- P/E (TTM)
- -17.2
- EPS (TTM)
- -$1.76
Volume 1.80M
Average 1.21M
NAMS Total Liabilities
Everything the company owes to creditors and other parties.
NewAmsterdam Pharma Company N.V.NASDAQ: NAMS
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 99.5% from a year ago
Total liabilities stood at $73.03M at the end of Q2 FY2026, up 99.5% from a year earlier and up 8.3% from the prior quarter. Over 3 fiscal years it compounded at +21.0% a year.
Context
- Total liabilities amounted to 10.4% of total assets at the end of Q2 FY2026, up 5.9 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +99.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 85.85M USD
- Year-over-year change
- -19.9%
- 4-year CAGR
- +65.8%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 85.85M | -19.9% |
| FY2024 | 2024-12-31 | 107.12M | +82.5% |
| FY2023 | 2023-12-31 | 58.7M | +21.2% |
| FY2022 | 2022-12-31 | 48.43M | +326.2% |
| FY2021 | 2021-12-31 | 11.36M | — |
Total Liabilities vs competitors
How NAMS compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +99.5% is the 4th highest of 9, against a peer median of +1.7%.
- Total liabilities amounts to 10.4% of total assets for NAMS, versus a peer median of 24.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $720.92M USD | +125.7% | +58.4% | 57.9% | |
| Jun 2026 | $322.78M USD | +131.9% | -32.0% | 27.9% | |
SEPNSepterna, Inc. | Sep 2026 | $191.48M USD | -12.1% | +38.7% | 30.9% |
| Jun 2026 | $113.58M USD | +250.7% | +48.9% | 21.8% | |
| Jun 2026 | $73.03M USD | +99.5% | +21.0% | 10.4% | |
| Mar 2026 | $46.15M USD | -5.7% | +88.6% | 34.5% | |
| Sep 2026 | $33.06M USD | +7.5% | -18.6% | 4.2% | |
BIOABioAge Labs, Inc. | Mar 2026 | $18.53M USD | -39.6% | -45.5% | 4.7% |
| Dec 2025 | A$2.65M AUD | -4.1% | -15.0% | 4.7% | |
| Peer median (excluding NAMS) | — | +1.7% | +11.9% | 24.8% | |
Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 60.38M | 467.73M | 340.45M | 771.74M | 490M |
| Short-term Investments | 0 | 0 | 0 | 62.45M | 146.24M |
| Net Receivables | 5.51M | 0 | 1.88M | 21.31M | 23.15M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | (627.81K) | 2.07M | 0 | 0 | 1.32M |
| Total Current Assets | 66.96M | 477.98M | 346.79M | 863.41M | 675.7M |
| Property, Plant & Equipment (Net) | 216.08K | 154K | 101K | 673K | 568K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 208K | 170K | 534K | 407K |
| Long-term Investments | 138.02M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (137.2M) | 156K | 35K | 0 | 92.61M |
| Total Non-current Assets | 1.03M | 518K | 306K | 1.21M | 93.58M |
| Total Assets | 67.99M | 478.5M | 347.1M | 864.62M | 769.28M |
| Account Payables | 7.07M | 11.85M | 16.92M | 4.74M | 8.97M |
| Short-term Debt | 0 | 0 | 0 | 0 | 136K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 8.94M | 6.01M | 3.99M |
| Other Current Liabilities | 0 | 18.02M | 15.96M | 91.03M | 72.69M |
| Total Current Liabilities | 11.24M | 36.06M | 49.9M | 106.92M | 85.79M |
| Long-term Debt | 0 | 0 | 0 | 0 | 66K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 1.02M | 0 | 0 |
| Other Non-current Liabilities | 0 | 12.31M | 7.79M | 0 | 0 |
| Total Non-current Liabilities | 126.24K | 12.37M | 8.81M | 202K | 66K |
| Total Liabilities | 11.36M | 48.43M | 58.7M | 107.12M | 85.85M |
| Common Stock | 128.51K | 10.06M | 10.17M | 13.44M | 14.28M |
| Retained Earnings | (39.44M) | (140.04M) | (316.97M) | (558.57M) | (762.39M) |
| Accumulated OCI | 672.13K | 4.42M | 4.42M | 4.47M | 4.79M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 56.63M | 430.07M | 288.39M | 757.5M | 683.43M |
| Total Debt | 186.51K | 126K | 60K | 448K | 202K |
| Net Debt | (60.19M) | (467.6M) | (340.39M) | (771.3M) | (489.8M) |
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
Intrinsic Alpha fair value
Locked
Current Price
$19.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.